Genevation LTD

Genevation Ltd develops ultra-fast, AI-driven, cell-free, non-LNP mRNA cancer vaccines, reducing development time from 8 weeks to just 2 weeks. Our precision-engineered, personalized immunotherapies target patient-specific tumor antigens, enhancing efficacy and safety. By combining AI-powered target identification with scalable mRNA technology, we revolutionize cancer treatment with faster, more effective, and accessible solutions.